AMRX News and Press, Amneal Pharmaceuticals Inc. Class A From 07/08/22

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its second quarter 2022 financial results on Friday August 5, 2022, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern T...

Generic drugmaker erased losses on Friday to add more than 27% after the company announced a that a federal jury in Chicago, Illinois issued a favorable verdict in an antitrust trial regarding its 2010 settlement with Amneal Pharmaceuticals ( AMRX ). Endo ( NASDAQ: END...

Amneal Pharmaceuticals (NYSE:AMRX) on Wednesday launched its oral Lyvispah granules for the treatment of abnormal muscle tightness, known as spasticity, caused due to spinal cord and neurological disorders. FDA-approved Lyvispah is bioequivalent to oral baclofen tablets and comes in thre...

- Provides the clinical benefits of baclofen in rapidly dissolvable granule formulation with flexible dosing for individual patient needs Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced the commercial launch o...

The U.S. Food and Drug Administration (FDA) approved Amneal Pharmaceuticals' (NYSE:AMRX) and Kashiv Biosciences' Fylnetra, a biosimilar to Amgen's (AMGN) Neulasta. Fylnetra (pegfilgrastim-pbbk) is used to treat neutropenia, a condition that occurs when there are fewer neutrophils, t...

- Marks Amneal’s third biosimilar approval in 2022 Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that the U.S. Food and Drug Administration (“FDA”) has approved the Company’s Biol...

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the “Company”) today announced that Chirag Patel, Co-Chief Executive Officer and President, and Tasos Konidaris, Chief Financial Officer, will participate at the 2022 Jefferies Healthcare Conference held on June 8, 2022 in New Yor...

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the “Company”) today announced that its investor relations or management team will attend the following investor conferences: RBC Healthcare Conference May 17, 2022 Investor Relations Hosted Meetings New York, New York ...

A group of generic drug manufacturers agreed to make versions of Pfizer’s (NYSE:PFE) COVID-19 antiviral Paxlovid at under US$25 per treatment course, The Clinton Health Access Initiative (CHAI) announced on Thursday. The health organization did not disclose the names of the drugmakers ...

The following slide deck was published by Amneal Pharmaceuticals, Inc. in conjunction with their 2022 Q1 earnings call. For further details see: Amneal Pharmaceuticals, Inc. 2022 Q1 - Results - Earnings Call Presentation